Clinical trials: Mismatch Repair Deficient Colorectal Cancer
Colorectal Cancer
Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer
The main purpose of this study was to help meet the medical needs of people in China with certain types of solid tumors that have specific genetic changes called microsatellite instability-high (MSI-H) or deficient mismatch…
- Trial name
- NCT05116085
- Testing
- Tislelizumab
- Where
- 8 sites in China
- Volunteers
- 33 people
- Sponsor
- BeiGene
Colorectal Cancer (MSI-H), Colorectal Cancer (CRC)
Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer
Patients with clinical stage II-III dMMR/MSI colorectal adenocarcinoma will be treated with low-dose immunotherapy: nivolumab 100 mg or pembrolizumab 100 mg. The duration of treatment is 6 months.
- Trial name
- NIVO1002024 (NCT07523763)
- Testing
- Nivolumab, Pembrolizumab
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Colorectal Cancer
Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer
In this phase II study patients with stage II-III MSI/dMMR colorectal adenocarcinoma with no signs of distant metastases will be treated with immunotherapy (prolgolimab). The duration of treatment is 6 months (12 cycles)
- Trial name
- NCT06428487
- Testing
- Prolgolimab
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Colorectal Cancer Metastatic, Mismatch Repair Deficiency
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Deficient mismatch repair (dMMR) or microsatellite instability high (MSI-H) accounts for 4-5% in metastatic colorectal cancer (mCRC).
- Conditions
- Colorectal Cancer Metastatic, Mismatch Repair Deficiency, Microsatellite Instability High
- Trial name
- NCT04482608
- Where
- China
- Volunteers
- 671 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumors, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214…
- Trial name
- NCT06004245
- Testing
- VVD-133214, Pembrolizumab, Bevacizumab
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 280 people
- Sponsor
- Vividion Therapeutics, Inc.
Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and…
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma, Recurrent Brain Neoplasm
- Trial name
- NCT02359565
- Testing
- Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Lynch Syndrome, Lynch Syndrome I
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals.
- Conditions
- Lynch Syndrome, Lynch Syndrome I, Lynch Syndrome II, Lynch Syndrome I (Site-specific Colonic Cancer)
- Trial name
- LYNX-EYE (NCT06708429)
- Testing
- LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
- Where
- 5 sites in United States, Italy
- Volunteers
- 300 people
- Sponsor
- San Raffaele University
Prostate Cancer, BRCA Mutation
The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer
The IMPACT study is an international targeted prostate screening study of men at increased prostate cancer risk due to the presence of known pathogenic mutations in BRCA1 and BRCA2 genes and Mis-Match Repair genes (MLH1, MSH6…
- Conditions
- Prostate Cancer, BRCA Mutation, Mismatch Repair Gene Mutation, Genetic Predisposition to Disease
- Trial name
- NCT00261456
- Testing
- PSA test, Prostate Biopsy
- Where
- United Kingdom
- Volunteers
- 3,500 people
- Sponsor
- Institute of Cancer Research, United Kingdom
MMR Mutation, Small Bowel Adenoma
Small Bowel Capsule Endoscopy in Lynch Syndrome
The impact of small bowel (SB) capsule endoscopy (CE) on the screening (followed by diagnosis and treatment) of (pre)neoplastic lesions of the small bowel in Lynch syndrome (LS) patients is unknown.
- Conditions
- MMR Mutation, Small Bowel Adenoma, Small-bowel Adenocarcinoma, Lynch Syndrome
- Trial name
- iCARE4Lynch (NCT07472686)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metastatic Colorectal Cancer
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or…
- Trial name
- CheckMate 8HW (NCT04008030)
- Testing
- Ipilimumab, Oxaliplatin, Leucovorin
- Where
- 157 sites in United States, Argentina and 22 more
- Volunteers
- 839 people
- Sponsor
- Bristol-Myers Squibb
Colon Cancer, Mismatch Repair Deficiency
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
Due to dMMR colon cancer patients respond poorly to conventional chemotherapy, but immunotherapy can significantly improve the pCR in this group of patients, this study intends to explore whether neoadjuvant immunotherapy can…
- Conditions
- Colon Cancer, Mismatch Repair Deficiency, Immunotherapy
- Trial name
- NITDC (NCT06215677)
- Testing
- Camrelizumab
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- Peking Union Medical College Hospital
Colon Cancer, Deficient Mismatch Repair
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
This prospective, multicenter, single-arm phase II interventional study evaluates whether longitudinal circulating tumor DNA (ctDNA) monitoring can guide neoadjuvant immunotherapy and surgical decision-making in dMMR/MSI-H colon…
- Conditions
- Colon Cancer, Deficient Mismatch Repair, Microsatellite Instability-High (MSI-H)
- Trial name
- NCT07841236
- Testing
- PD-1 inhibitor, CTLA-4 inhibitor, ctDNA/MRD testing
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Fudan University
Colorectal Cancer
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of cemiplimab and the combination of cemiplimab/fianlimab in microsatellite unstable localized or locally advanced colorectal cancer diagnosed in patients…
- Trial name
- NCT06205836
- Testing
- Cemiplimab, Fianlimab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc
Colorectal Carcinoma
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
In this open-label phase III study, patients with local advanced colon cancer (TanyN+ ,M0, dMMR/MSI-H, at least 10cm from the anus verge)will be scheduled to Group A: receive anti-PD-1 antibody alone (8 cycles, 200mg iv drip Q3W)…
- Trial name
- NCT05236972
- Testing
- Sintilimab, Oxaliplatin, capecitabine
- Where
- China
- Volunteers
- 323 people
- Sponsor
- Sun Yat-sen University
Colon Cancer
Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.
The goal of this investigational, multicenter, open-label randomized, two-stage phase II study is to evaluate neoadjuvant pembrolizumab with a watch-and-wait approach in patients with localized deficient mismatch repair / high…
- Trial name
- PREMICES (NCT06646445)
- Testing
- Pembrolizumab Injection [Keytruda], Watch-and-wait approach, Surgery
- Where
- 10 sites in France
- Volunteers
- 60 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Colorectal Cancer
Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer
Colorectal cancer is one of the most common malignant tumors, accounting for approximately 10% of new cancer cases and cancer-related deaths worldwide each year.
- Trial name
- NCT06698757
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Yugui Lian
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Neoplasm Metastasis
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
- Trial name
- NCT04458259
- Testing
- PF-07265807, Sasanlimab, Axitinib
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 88 people
- Sponsor
- Pfizer
MSI, dMMR Colorectal Cancer
Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer
MSI is a molecular indicator of defective DNA mismatch repair (dMMR). The MSI/dMMR status is observed in all tumor types, representing notably 5% of metastatic colorectal cancers (mCRC), 25% of advanced endometrial cancer and 8%…
- Trial name
- MONAMI (NCT06152523)
- Testing
- Monalizumab/MEDI5257
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris